OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
(4) - EconoTimes)
DUBLIN, IRELAND, May 04, 2018 -- Horizon Pharma plc (NASDAQ:HZNP) today announced that the compensation committee of its board of directors approved the grant on May 1, 2018 of inducement restricted stock units for an aggregate of 228,305 ordinary shares to 30 new employees.
Certain of the restricted stock units vest over four years, with 25 percent of the shares vesting on each anniversary of the applicable vesting commencement date, and certain of the restricted stock units vest over three years, with 1/3 of the shares vesting on each anniversary of the applicable vesting commencement date. All awards are subject to the new employee's continued service relationship with the Company. Each restricted stock unit also is subject to the terms and conditions of the Company's 2014 Equity Incentive Plan and the restricted stock unit agreement pursuant to which the restricted stock unit was granted.
The restricted stock units were granted as inducements material to the new employees entering into employment with Horizon Pharma in accordance with NASDAQ Listing Rule 5635(c)(4).
About Horizon Pharma plc
Horizon Pharma plc is focused on researching, developing and commercializing innovative medicines that address unmet treatment needs for rare and rheumatic diseases. By fostering a growing pipeline of medicines in development and exploring all potential uses for currently marketed medicines, we strive to make a powerful difference for patients, their caregivers and physicians. For us, it’s personal: by living up to our own potential, we are helping others live up to theirs. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter, like us on Facebook or explore career opportunities on LinkedIn.
Contacts:
Tina Ventura
Senior Vice President, Investor Relations
[email protected]
Ruth Venning
Executive Director, Investor Relations
[email protected]
U.S. Media Contact:
Geoffrey Curtis
Senior Vice President, Corporate Affairs and Chief Communications Officer
[email protected]
Ireland Media Contact:
Ray Gordon
Gordon MRM
[email protected]
